• Pharmacokinetic Variability of CSBTA in MASH Mouse Models

  2026-05-09

  This study systematically investigates how metabolic dysfunction-associated steatohepatitis (MASH) alters the pharmacokinetics and tissue distribution of Corydalis saxicola Bunting total alkaloids (CSBTA) in mice. By identifying the roles of CYP450 enzymes, transporters, and the pregnane X receptor (PXR) in mediating these effects, the work provides critical guidance for optimizing dosage regimens in MASLD/MASH research and therapy.

• 5-hme-dCTP: Advanced Platform for DNA Hydroxymethylation Map

  2026-05-08

  Explore the scientific and practical advances of 5-hme-dCTP (5-Hydroxymethyl-2’-deoxycytidine-5’-Triphosphate) for high-resolution epigenetic DNA modification research. This article delivers unique, method-focused insight and actionable protocol guidance.

• Patient-Derived Gastric Cancer Assembloids: Modeling Tumor-S

  2026-05-08

  This study presents a robust patient-derived gastric cancer assembloid model integrating matched tumor organoids with stromal cell subpopulations, effectively capturing tumor microenvironment complexity. The model reveals stromal influence on drug response and resistance, enabling improved preclinical drug screening and personalized therapy optimization.

• Deciphering In Vitro Drug Response Metrics in Cancer Researc

  2026-05-07

  Schwartz (2022) rigorously dissects how proliferative arrest and cell death are measured in anti-cancer drug evaluation, demonstrating that conventional metrics can conflate distinct biological outcomes. This work prompts a more nuanced interpretation of in vitro drug efficacy, with direct implications for selecting and benchmarking HDAC inhibitors like Entinostat (MS-275) in cancer research.

• Clinical Relevance of Circulating Giant Cancer Macrophages i

  2026-05-07

  This study provides the first prospective, multi-institutional evidence that circulating polyploid giant cancer macrophages (CAMLs) are strongly associated with disease progression across multiple solid tumor types. By characterizing CAMLs' unique phenotypes and their role in pre-metastatic niche formation, the research opens new avenues for early detection and monitoring of metastatic risk.

• Indazole/Indole Glucagon Receptor Antagonists: Synthesis and

  2026-05-06

  This study presents the rational design and synthesis of novel indazole- and indole-based glucagon receptor antagonists as candidate therapeutics for type 2 diabetes mellitus. The research details structure–activity relationships and highlights synthetic strategies—including advanced amide bond formation methods—to achieve potent molecules with favorable pharmacological profiles.

• Precision Targeting of AAA with Doxycycline-Loaded Polypheno

  2026-05-06

  This study introduces a multifunctional nanomedicine that leverages tea polyphenol nanoparticles for the targeted delivery of doxycycline to abdominal aortic aneurysm (AAA) lesions. By enhancing lesion-specific accumulation and controlled drug release, the approach addresses multiple pathological mechanisms underlying AAA progression and highlights a promising strategy for vascular disease therapy.

• Capsazepine as an MCL1 Inhibitor to Reverse Tamoxifen Resist

  2026-05-05

  A recent study identifies capsazepine as a novel and direct MCL1 inhibitor, demonstrating its ability to overcome tamoxifen resistance in ER+ breast cancer models. Through a combination of virtual screening, molecular docking, and functional assays, capsazepine was shown to induce apoptosis and synergize with tamoxifen, highlighting new therapeutic strategies for endocrine-resistant breast cancer.

• Angiotensin 1/2 (5-7): Protocol Innovations in RAS Research

  2026-05-05

  Angiotensin 1/2 (5-7) unleashes new precision in renin-angiotensin system assays and viral pathogenesis studies. This guide translates recent mechanistic breakthroughs into actionable protocols and troubleshooting strategies, empowering researchers in cardiovascular and infectious disease domains.

• HR Repair Profiling Predicts PARP Inhibitor Response in Meso

  2026-05-04

  Borchert et al. (2019) demonstrate that gene expression patterns within the homologous recombination (HR) repair pathway, notably the BRCAness phenotype, predict susceptibility to olaparib in malignant pleural mesothelioma (MPM) cell lines. Their findings suggest that stratifying patients by HR pathway alterations can inform targeted therapeutic strategies, especially in the context of BAP1 mutations.

• Dual-Action Kinase Inhibitors Modulate p38α MAPK Dephosphory

  2026-05-04

  This study uncovers how certain kinase inhibitors can simultaneously block kinase activity and promote dephosphorylation of p38α MAP kinase by stabilizing a phosphatase-accessible activation loop conformation. These findings introduce a new mechanistic strategy for designing kinase inhibitors with enhanced specificity and functional impact in signal transduction research.

• Dual Metrics for In Vitro Cancer Drug Response: Insights fro

  2026-05-03

  Schwartz's dissertation critically examines how in vitro measurement strategies—specifically, the distinction between relative and fractional viability—impact the interpretation of anti-cancer drug responses. The work demonstrates that most agents, including HDAC inhibitors like Entinostat (MS-275), simultaneously affect cancer cell proliferation and induce cell death, but in different proportions and with distinct temporal dynamics, emphasizing the importance of nuanced assay selection in preclinical research.

• Cediranib (AZD2171) in Quantitative Angiogenesis: From Pathw

  2026-05-02

  Explore Cediranib (AZD2171) as a next-generation angiogenesis inhibitor for cancer research. This article uniquely emphasizes quantitative assay design and interpretation, grounded in systems-biology insights and the latest in vitro evaluation methodologies.

• Afatinib (BIBW 2992) in Advanced Tumor Assembloid Research

  2026-05-01

  Afatinib (BIBW 2992) empowers oncology researchers to dissect ErbB signaling and resistance mechanisms in physiologically relevant assembloid models. This guide delivers practical setup, protocol optimization, and troubleshooting strategies, directly integrating the latest assembloid innovations to enhance cancer biology research.

• PDK4-IN-1 Hydrochloride: Precision PDK4 Inhibitor for Metabo

  2026-05-01

  PDK4-IN-1 hydrochloride empowers researchers to dissect mitochondrial energy metabolism with nanomolar selectivity, enabling precise control in metabolic, oncological, and cardiac hypertrophy models. Its robust workflow integration and troubleshooting versatility, backed by landmark studies, establish it as a cornerstone for translational metabolic research.

16441 records 1/1097 page Next 12345 下5页 Last page